China GMP
Form: tablet
Strength: 20mg, 50mg
Indication: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>This category refers to <strong>oral therapeutic tablets</strong> designed for systemic treatment. Manufactured under strict <strong>GMP standards</strong>, these products utilize purified active pharmaceutical ingredients combined with standard excipients to ensure stability and bioavailability.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Clinics:</strong> Primary use in managing hematological malignancies and solid tumors.</li>
<li><strong>Hospital Pharmacies:</strong> Dispensing for inpatient chemotherapy regimens and outpatient maintenance.</li>
<li><strong>Research Laboratories:</strong> Utilized in preclinical trials to evaluate efficacy and toxicity profiles.</li>
</ul>
<h3>Precautions</h3>
<ul>
<li><strong>Storage:</strong> Must be kept in controlled temperature environments to prevent degradation.</li>
<li><strong>PPE:</strong> Handlers require gloves and masks to avoid dermal exposure during bulk handling.</li>
<li><strong>Replacement:</strong> Periodic inventory audits are mandatory to ensure batch validity before expiration.</li>
</ul>